174 related articles for article (PubMed ID: 38160567)
1. Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor.
Yu J; Xiong F; Xu Y; Xu H; Zhang X; Gao H; Li Y
Int Immunopharmacol; 2024 Jan; 127():111412. PubMed ID: 38160567
[TBL] [Abstract][Full Text] [Related]
2. Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors.
Cook S; Samuel V; Meyers DE; Stukalin I; Litt I; Sangha R; Morris DG; Heng DYC; Pabani A; Dean M; Navani V
JAMA Netw Open; 2024 Jan; 7(1):e2352302. PubMed ID: 38236598
[TBL] [Abstract][Full Text] [Related]
3. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
5. The Predictive Model Construction for Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy.
Gao W; Liu Q; Zhou Y; Yang M; Yu Y
Technol Cancer Res Treat; 2023; 22():15330338231206705. PubMed ID: 37927008
[TBL] [Abstract][Full Text] [Related]
6. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
[TBL] [Abstract][Full Text] [Related]
7. New biomarkers exploration and nomogram construction of prognostic and immune-related adverse events of advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors.
Lin X; Chen X; Long X; Zeng C; Zhang Z; Fang W; Xu P
Respir Res; 2023 Feb; 24(1):64. PubMed ID: 36849947
[TBL] [Abstract][Full Text] [Related]
8. Prediction of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint inhibitors based on clinical and hematological markers: Real-world evidence.
Xu H; Feng H; Zhang W; Wei F; Zhou L; Liu L; Zhao Y; Lv Y; Shi X; Zhang J; Ren X
Exp Cell Res; 2022 Jul; 416(1):113157. PubMed ID: 35427598
[TBL] [Abstract][Full Text] [Related]
9. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
10. Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
Akamatsu H; Murakami E; Oyanagi J; Shibaki R; Kaki T; Takase E; Tanaka M; Harutani Y; Yamagata N; Okuda Y; Furuta K; Sugimoto T; Teraoka S; Hayata A; Tokudome N; Ozawa Y; Mori K; Koh Y; Yamamoto N
Oncologist; 2020 Apr; 25(4):e679-e683. PubMed ID: 32297443
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy.
Wang H; Zhou F; Zhao C; Cheng L; Zhou C; Qiao M; Li X; Chen X
Front Immunol; 2022; 13():840313. PubMed ID: 35222434
[TBL] [Abstract][Full Text] [Related]
12. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
13. Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter retrospective study.
Fujimoto A; Koutake Y; Hisamatsu D; Ookubo N; Yabuuchi Y; Kamimura G; Kai T; Kozono A; Ootsu T; Suzuki H; Matsuo K; Kuwahara K; Oiwane Y; Nagata Y; Tanimoto K; Sato E; Suenaga M; Uehara T; Ikari A; Endo S; Hiraki Y; Kawamata Y
Cancer Immunol Immunother; 2023 Jul; 72(7):2169-2178. PubMed ID: 36849845
[TBL] [Abstract][Full Text] [Related]
14. Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Huang DD; Liao BC; Hsu WH; Yang CY; Lin YT; Wu SG; Tsai TH; Chen KY; Ho CC; Liao WY; Shih JY; Yu CJ; Yang JC; Cheng AL; Shen YC
Oncology; 2024; 102(4):318-326. PubMed ID: 37778345
[TBL] [Abstract][Full Text] [Related]
15. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
Front Immunol; 2021; 12():760737. PubMed ID: 34925331
[TBL] [Abstract][Full Text] [Related]
16. Immune-related adverse events as potential surrogates of immune checkpoint inhibitors' efficacy: a systematic review and meta-analysis of randomized studies.
Amoroso V; Gallo F; Alberti A; Paloschi D; Ferrari Bravo W; Esposito A; Cosentini D; Grisanti S; Pedersini R; Petrelli F; Berruti A
ESMO Open; 2023 Apr; 8(2):100787. PubMed ID: 36842300
[TBL] [Abstract][Full Text] [Related]
17. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
[TBL] [Abstract][Full Text] [Related]
18. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
Kalinich M; Murphy W; Wongvibulsin S; Pahalyants V; Yu KH; Lu C; Wang F; Zubiri L; Naranbhai V; Gusev A; Kwatra SG; Reynolds KL; Semenov YR
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789879
[TBL] [Abstract][Full Text] [Related]
19. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
[TBL] [Abstract][Full Text] [Related]
20. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.
Wang M; Liang H; Wang W; Zhao S; Cai X; Zhao Y; Li C; Cheng B; Xiong S; Li J; He J; Liang W
Cancer; 2021 Mar; 127(5):777-786. PubMed ID: 33119182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]